Association of Serum TGF-β1 Levels with Different Clinical Phenotypes of Cystic Fibrosis Exacerbation

  • 44 Accesses



Cystic Fibrosis (CF) is a multi-organ genetic disorder and Transforming Growth Factor (TGF-β1) is a modifier gene which modulates lung pathology in CF. There is great phenotypic variability among CF patients who even have similar genotype. The aim of the present study was to associate the serum levels of TGF-β1 with several clinical phenotypes of CF.


The diagnosed cases of CF were recruited and the blood sample was withdrawn at different time points: during exacerbation (n = 26), non-exacerbation (n = 9) and after antibiotic therapy (n = 11). The concentration of the total TGF-β1 in serum was measured with commercial ELISA kit. The ΔF508 mutation was assessed by the Amplification Refractory Mutation System (ARMS-PCR).


The levels of TGF-β1 were increased in exacerbation phase (119.89 ± 29.64 ng/mL), infection with P. aeruginosa (121.8 ± 28.83 ng/mL) and in subjects with ΔF508 mutation (139.2 ± 19.59 ng/mL). The levels of TGF-β1 in CF patients with Allergic Bronchopulmonary Aspergillosis (ABPA) (109.97 ± 27.71 ng/mL) were decreased as compared to CF patients without ABPA (123.55 ± 30.20 ng/mL). It was observed that the serum levels of TGF-β1 were decreased significantly after antibiotic therapy (p < 0.05).


The present study has determined that the serum levels of TGF-β1 vary with the type of infections, ΔF508 CFTR mutation, presence of ABPA and response to therapy.

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 39.95

Price includes VAT for USA

Subscribe to journal

Immediate online access to all issues from 2019. Subscription will auto renew annually.

US$ 99

This is the net price. Taxes to be calculated in checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6


  1. 1.

    Boucher RC (2004) New concepts of the pathogenesis of cystic fibrosis lung disease. Eur Respir J 23(1):146–158

  2. 2.

    Kerem E, Corey M, Kerem B et al (1990) The relation between genotype and phenotype in cystic fibrosis—analysis of the most common mutation (ΔF508). N Engl J Med 323(22):1517–1522

  3. 3.

    Drumm ML, Konstan MW, Schluchter MD, Handler A, Pace R, Zou F et al (2005) Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med 353(14):1443–1453

  4. 4.

    Bremer LA, Blackman SM, Vanscoy LL, McDougal KE, Bowers A, Naughton KM et al (2008) Interaction between a novel TGFB1 haplotype and CFTR genotype is associated with improved lung function in cystic fibrosis. Hum Mol Genet 17(14):2228–2237

  5. 5.

    Magnan A, Frachon I, Rain B, Peuchmaur M, Monti G, Lenot B et al (1994) Transforming growth factor β in normal human lung: preferential location in bronchial epithelial cells. Thorax 49(8):789–792

  6. 6.

    Flanders KC (2004) Smad3 as a mediator of the fibrotic response. Int J Exp Pathol 85(2):47–64

  7. 7.

    Arkwright PD, Laurie S, Super M, Pravica V, Schwarz MJ, Webb AK et al (2000) TGF-beta(1) genotype and accelerated decline in lung function of patients with cystic fibrosis. Thorax 55(6):459–462

  8. 8.

    Haston CK, Hudson TJ (2005) Finding genetic modifiers of cystic fibrosis. N Engl J Med 353(14):1509–1511

  9. 9.

    Harris WT, Muhlebach MS, Oster RA et al (2009) Transforming growth factor-beta(1) inbronchoalveolar lavage fluid from children with cystic fibrosis. Pediatr Pulmonol 44(11):1057–1064

  10. 10.

    Harris WT, Muhlebach MS, Oster RA, Knowles MR, Clancy JP, Noah TL (2011) Plasma TGF-β(1) in pediatric cystic fibrosis: potential biomarker of lung disease and response to therapy. Pediatric Pulmonol 46(7):688–695

  11. 11.

    Schwarz KB, Rosensweig J, Sharma S, Jones L, Durant M, Potter C, Narkewicz MR (2003) Plasma markers of platelet activation in cystic fibrosis liver and lung disease. J Pediatric Gastroenterol Nutr 37(2):187–191

  12. 12.

    Snodgrass SM, Cihil KM, Cornuet PK, Myerburg MM, Swiatecka-Urban A (2013) Tgf-b1 inhibits Cftr biogenesis and prevents functional rescue of ΔF508-Cftr in primary differentiated human bronchial epithelial cells. PLoS ONE 8(5):e63167

  13. 13.

    Sun H et al (2014) Tgf-beta downregulation of distinct chloride channels in cystic fibrosis-affected epithelia. PLoS ONE 9:e106842

  14. 14.

    Collaco JM, Cutting GR (2008) Update on gene modifiers in cysticfibrosis. Curr Opin Pulm Med 14:559–566

  15. 15.

    Bilton D, Canny G, Conway S et al (2011) Pulmonary exacerbation: towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials. J Cyst Fibros 10:S79–S81

  16. 16.

    Stevens DA, Moss RB, Kurup VP, Knutsen AP, Greenberger P, Judson MA et al (2003) Allergic bronchopulmonary aspergillosis in cystic fibrosis—state of the art: cystic fibrosis foundation consensus conference. Clin Infect Dis 37(3):S225–S264

  17. 17.

    Ferrie RM, Schwarz MJ, Robertson NH, (1992) Development, multiplexing and application of ARMS tests for common mutations in the CFTR gene. Am J Hum Genet 5:149–155

  18. 18.

    Eickmeier O, Boom L, Schreiner F, Lentze MJ, NGampolo D, Schubert R, et al (2013) Transforming growth factor β1 genotypes in relation to TGFβ1, interleukin-8, and tumor necrosis factor alpha in induced sputum and blood in cystic fibrosis. Med Inflamm 2013:913135

  19. 19.

    Corvol HBP, Brouard J, Knauer N, Chadelat K, Henrion-Caude A, Flamant C et al (2008) Genetic variations in inflammatory mediators influence lung disease progression in cystic fibrosis. Pediatr Pulmonol 43(12):1224–1232

  20. 20.

    Dawson KP, Frossard PM, Al-Awar B (2001) Disease severity associated with cysticfibrosis mutations deltaF508 and S549R(T–%3eG). East Mediterr Health J 7(6):975–980

  21. 21.

    Mitash N, Mu F, Donovan JE, Myerburg MM, Ranganathan S, Greene CM, Swiatecka-Urban A (2019) Transforming growth factor-β1 selectively recruits microRNAto the RNA-induced silencing complex and degrades CFTR mRNA under permissive conditions in human bronchial epithelial cells. Int J Mol Sci 20(19):4933

  22. 22.

    Knutsen AP et al (2019) T cell cytokine synthesis in cystic fibrosis patients with allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 113(2):S278

  23. 23.

    Maloney JP, Narasimhan J, Biller J (2019) Decreased TGF-β1 and VEGF release in cystic fibrosis platelets: further evidence for platelet defects in cystic fibrosis. Lung 194(5):791–798

Download references


Indian Council of Medical Research, New Delhi.


The study was supported by Indian Council of Medical Research, New Delhi through grant no: ICMR JRF No. 3/1/3/JRF-2012/HRD-08 (10835).

Author information

SS was involved in conceptualizing the research proposal, performed all experimental procedures and wrote the manuscript. AC was involved in genetic analysis of CFTR mutation and wrote the manuscript. JK and RP provided the laboratory facilities and helped in analysing the data. MS (Meenu Singh) was responsible for patient recruitment, obtaining informed consent and data analysis. MS (Manvi Singh) was involved in patient recruitment.

Correspondence to Meenu Singh.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Sagwal, S., Chauhan, A., Kaur, J. et al. Association of Serum TGF-β1 Levels with Different Clinical Phenotypes of Cystic Fibrosis Exacerbation. Lung (2020) doi:10.1007/s00408-020-00320-x

Download citation


  • Cystic fibrosis
  • TGF-β
  • Exacerbation
  • ABPA
  • ΔF508 CFTR mutation